GRI Bio, Inc.

Stage 1 · Basing · week 5

As of Oct 22, 2026, GRI Bio is in Stage 1, the basing phase, now in week 5 (since Sep 21, 2026). It closed at $1.42, 97.6% below its 52-week high and below its 200-day average, which is falling.

$1.42

-3.40% today

$3.1M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is GRI early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 63w

S4 26w

S1 19w

S4 40w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 63w → S1 12w → S4 26w → S1 19w → S4 40w → S1 5w current

Total tracked: 166 weeks across 6 stage runs.

GRI among Biotechnology536th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…536	GRIGRI Bio, Inc.	Stage 1 · wk 5	4	−34.0%

vs 52W High

-97.6%

$1.38 lo$59.92 hi

97.6% below 52W high

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 5

1w13w26w

Week 5, early base

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

-40.8%

200 DMA: $2.40 · sloping down

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

0.08x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-34.0%

-2.1%

-41.1%

YTD

-81.9%

-97.8%

Scan Membership

Breakout Watch

Latest: 2023-03-09

3 appearances in last 60 days. First seen: 2022-01-10.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S1

Wk 5 · Vol 0.08x

2026-10-21S1

Wk 5 · Vol 0.14x

2026-10-20S1

Wk 5 · Vol 0.11x

2026-10-19S1

Wk 5 · Vol 0.10x

2026-10-16S1

Wk 4 · Vol 0.11x

2026-10-15S1

Wk 4 · Vol 0.07x

2026-10-14S1

Wk 4 · Vol 0.12x

2026-10-13S1

Wk 4 · Vol 0.07x

2026-10-12S1

Wk 4 · Vol 0.16x

2026-10-09S1

Wk 3 · Vol 0.05x

2026-10-08S1

Wk 3 · Vol 0.13x

2026-10-07S1

Wk 3 · Vol 0.08x

Moving averages & range

50 DMA

$1.84

200 DMA

$2.40

52W High

$59.92

52W Low

$1.38

5D Low

$1.38

Resistance levels (recent highs)

20d High

$2.10

60d High

$2.88

120d High

$2.88

250d High

$59.92

Next resistance

+47.9%

to 20d High

ROE

-142.0%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.3

GRI Bio: quick answers

What stage is GRI Bio in?

As of Oct 22, 2026, GRI Bio (GRI) is in Stage 1, the basing phase. It entered Stage 1 on Sep 21, 2026 and is in week 5. What the four stages mean

Is GRI Bio in an uptrend?

Not yet. GRI Bio is in Stage 1, a base that can come before an uptrend. It trades 40.8% below its 200-day average, which is falling.

How far is GRI Bio from its 52-week high?

GRI Bio closed at $1.42 on Oct 22, 2026, 97.6% below its 52-week high of $59.92. Its 52-week low is $1.38.

How has GRI Bio performed over the past year?

As of Oct 22, 2026, GRI Bio is down 97.8% over the past year and down 81.9% so far in 2026.

Which sector and industry is GRI Bio in?

GRI Bio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.